Juhana Rauramo will become the new CEO of HyTest Group Oy with effect from January 1, 2021. Juhana has proven to be a very valuable person for HyTest and he has agreed to take on a more extensive role regarding the management of the company. Meanwhile, Maria Severina, the Founder and CEO of the company for the last 26 years will continue as a board member for HyTest Group Oy and she will be available as a consultant to the company.

Juhana has been the CCO of HyTest and a member of the management team since September 2019. He has previously held management positions in various companies in the in vitro diagnostics, pharmaceutical, and venture capital industries. “I have a great team around me and working together we will be able to take the next steps in developing the company. For example, during this very challenging year we have been able to launch a range of products for COVID-19-related markers to address the needs of this rapidly emerging market. My vision is for us to become the world’s number one choice when selecting antibodies and antigens for in vitro diagnostic tests,” explains Juhana Rauramo.

Maria Severina:” Our goal since we started all those years ago has been to improve health by providing access to the latest research and technology in the arena of antibodies and antigens for diagnostic use to the market. Having Juhana on board has enabled us to provide even better support to our customers regarding their projects and with Juhana as the new CEO we will be able to take the next step in terms of developing our company and further benefitting our valued customers.”

HyTest produces antibodies and antigens for the IVD industry for use as key components of various laboratory assays and kits. The company has gained a market leading position in several key market segments, including cardiac markers and influenza testing reagents. HyTest’s primary customer segments are the IVD industry and large international research groups.